

24-Dec-2022

BMJ-2022-070730.R1

Surgical versus non-surgical treatment for sciatica: a systematic review and meta-analysis of randomised controlled trials

Dear Dr. Liu

Thank you for sending us your revised paper and for your patience while we have been considering it.

We still recognise the potential importance of your paper and its relevance to general medical readers, but we have not yet been able to reach a final decision on it because several important aspects of the work still need clarifying.

We sent it back to the original peer reviewers and discussed it among editors. We believe that the revisions have improved the manuscript and addressed a number of our comments from the first round of review, however a few queries still remain.

We hope very much that you will be willing and able to revise your paper in response to the peer reviewers and editors listed below. Please do not hesitate to get in touch if you wish to discuss any of the comments. We are looking forward to reading the revised version and, we hope, reaching a decision.

Yours sincerely,

Dr Navjoyt Ladher  
Research Editor  
nladher@bmj.com

To start your revision, please click this link or log in to your account: \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. \*\*\*

[https://mc.manuscriptcentral.com/bmj?URL\\_MASK=1034eaaeda4441d68b9c2b8e4064177b](https://mc.manuscriptcentral.com/bmj?URL_MASK=1034eaaeda4441d68b9c2b8e4064177b)

**\*\*Comments from editors\*\***

Thank you for your hard work on the resubmitted manuscript. Your revisions have improved the manuscript, and we are reassured that your paper is adding to earlier work. However we note that there are still some concerns raised by the peer reviewers.

We felt that the two key points raised by reviewers could be discussed in more depth in the manuscript, specifically:

1. The heterogeneity of non-surgical treatment options
2. The framing of the research question and population

If possible, we would suggest revising the paper so that these issues are explored and discussed with more nuance.

**\*\* Comments from the external peer reviewers\*\***

Reviewer: 1

Recommendation:

Comments:

The authors have addressed some of my findings. Their answer that a 2020 Cochrane review found little difference between ESI types is not sufficient (I was an author on that paper). If there were no differences, there would be no transforaminal ESI since these are riskier. There are other reviews that find different outcomes, and TFESI are generally not used for bilateral pain (unless someone does 2 injections).

As someone who does intradiscal injections, I also cannot agree with lumping a percutaneous intradiscal injection with open spine surgery. This opens up all sorts of possibilities (what about nucleoplasty or other percutaneous treatments). These procedures do not require an operating room (can be done in a simple fluoroscopy suite).

Additional Questions:

**The BMJ** uses compulsory open peer review. Your name and institution will be included with your comments when they are sent to the authors. If the manuscript is accepted, your review, name and institution will be published alongside the article.

If this manuscript is rejected from **The BMJ**, it may be transferred to another BMJ journal along with your reviewer comments. If the article is selected for publication in another BMJ journal, depending on the editorial policy of the journal your review may also be published. You will be contacted for your permission before this happens.

For more information, please see our [peer review terms and conditions](https://www.bmj.com/about-bmj/resources-reviewers).

**Please confirm that you understand and consent to the above terms and conditions:**  
I consent to the publication of this review

Please enter your name: Steven P. Cohen

Job Title: Chief of Pain Medicine

Institution: Johns Hopkins

Reimbursement for attending a symposium?: No

A fee for speaking?: No

A fee for organising education?: No

Funds for research?: No

Funds for a member of staff?: No

Fees for consulting?: No

Have you in the past five years been employed by an organisation that may in any way gain or lose financially from the publication of this paper?: No

Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper?: No

If you have any competing interests <a href="http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests" target="\_new"> (please see BMJ policy) </a> please declare them here:

<em>BMJ are working with <a href="https://orcid.org/" target="\_blank">ORCID</a> to recognise the importance of the reviewer community. Reviewers are now able to share their activity by connecting their review to their ORCID account to gain recognition for their contributions.</em>

Only the Journal title will be uploaded into the reviewer's ORCID record, along with the date the record was uploaded; there is no identification of the article's title or authors. Records are uploaded once a decision (accept, reject, or revision) has been made on the article.</em>

Would you like to be accredited by <a href="https://orcid.org/" target="\_blank">ORCID</a> for this review?: No

Reviewer: 2

Recommendation:

Comments:

I would like to thank the authors for revising their manuscript. I believe it has further improved. I have some additional small comments, but importantly have to insist on my original concern about the selective population reported on in this meta-analysis and the misleading title/conclusions. I do not think the authors have addressed my concern and I do think this needs to be addressed more carefully before publication can be considered. Below I try to explain again why I think the current conclusions are overstated/misleading.

I have to insist on my previous concern that the conclusions are overstated and simply not accurate if we look at the wide heterogeneity of sciatica. To state that discectomy is an option for people with sciatica is not correct, the findings suggest it seems an option for people with sciatica with a surgical indication. As I pointed out before, the vast majority of patients with sciatica will not have any surgical indication and would therefore simply never be considered for these studies (1. It would be unethical and 2. surgeons would not operate if there is no structural correlate (e.g., disc herniation) or clear clinical indication to operate).

The authors point out in their reply to my concern (nr 27) that their review only included patients with an MRI confirmed disc herniation. However, as the authors must be aware, disc herniations are very common, even in healthy people. The mere presence of a disc herniation is not the only deciding factor for surgery. So even if the studies do not report failed conservative management (and thank you to the authors for checking this) or how exactly the surgeons decided it was ok to offer surgery, the population in the studies must be a very select population, which have 1) disc herniation and 2) a clinical picture that makes surgeons offer surgery (e.g., severe or progressive weakness; uncontrollable pain, please refer to international guidelines on this such as NICE). So, the patients in these studies do not only have a disc herniation, but they also do have a surgical indication. And in fact not very many patients with sciatica have this. I do not think that the authors made this clear enough in the discussion section.

Unfortunately, I feel strongly about this point as it is misleading to suggest that discectomy is an option for (all) patients with sciatica. Currently, the abstract/title/conclusion in discussion implies that. There is a responsibility of researchers to be accurate, as patients more and more inform themselves in the medical literature, and the current conclusions leave much room for misinterpretation (also for clinicians).

I suggest to carefully discuss this issue in the discussion section (e.g., the select group of patients likely included in these studies) and also change the title and conclusions in both discussion and abstract to more accurately reflect the patient population (rather than just saying 'sciatica'). Please also amend the 'what this paper adds' section. The conclusion could read as follows:

Discectomy may be an option for people with sciatica with a surgical indication, who feel that the rapid relief offered by discectomy outweighs the risks and costs associated with surgery.

Methods section on subgroup and exploratory meta-regression: please specify in this part which ones were pre-planned/posthoc analyses.

Typo/grammar page 13: In trials without 'failing non-surgical treatment' in the inclusion criteria, discectomy had larger effects in reducing leg pain at immediate term (MD -19.3, 95% CI -30.4 to -8.2 vs MD -1.2 95% CI -5.5 to 3.1) and improving disability at short term (MD -10.6, 95% CI -14.0 to -7.3 vs MD -1.3, 95% CI -9.8 to 7.3) than trials which only included participants who had failed long term non-surgical treatment.

Also, why do you specify long-term non-surgical treatment in this sentence? In the methods you only stated that you distinguished failed vs non failed conservative treatment with no reference to timing? I do not think you should include only long term non-surgical treatment here as non-surgical treatment failure, but also studies that included patients with failed short term non-surgical treatment as per current guidelines (e.g., NICE recommends surgery consideration after 6 weeks of uncontrollable pain). Also, please label this analysis as a posthoc analysis both in methods and results.

Discussion:

Page 14: "Different from recent reviews, 13 15 16 we included trials conducted in a homogeneous population/surgical procedure/comparator, studies published in English and other languages, 27 33 39 43 47 and new robust trials published recently, 50-53 55 making this review the most comprehensive update on the evidence for the surgical management of sciatica that can provide more informative and nuanced results than the recent network meta-analysis which lumped results across all timepoint into one value."

Please revise this sentence. It is too long. Also, I suggest the authors remain more humble in their writing, e.g., their meta-analysis does indeed provide more nuanced data on certain things (e.g., separate time points), however the network meta-analysis had other findings which were more nuanced than those achieved in this present review (e.g., the network analysis). I simply suggest to remove the last part.

Limitations: "Reporting of non-surgical comparators was generally poor, with most trials failing at describing what types of treatments participants received, who provided these treatments, how they were provided and how much treatment they received."

Please make it clear to the audience that you lumped any kind of non-surgical interventions together and that these were not only poorly reported, but also highly heterogenous.

Supplemental file 20c, d: it seems that the meta-regression on duration of symptoms was done on dichotomized data? This should have been done on continuous data to avoid information loss.

Additional Questions:

**<em>The BMJ</em> uses compulsory open peer review. Your name and institution will be included with your comments when they are sent to the authors. If the manuscript is accepted, your review, name and institution will be published alongside the article.</strong>**

If this manuscript is rejected from <em>The BMJ</em>, it may be transferred to another BMJ journal along with your reviewer comments. If the article is selected for publication in another BMJ journal, depending on the editorial policy of the journal your review may also be published. You will be contacted for your permission before this happens.

For more information, please see our <a href="https://www.bmj.com/about-bmj/resources-reviewers" target="\_blank">peer review terms and conditions</a>.

**<strong>Please confirm that you understand and consent to the above terms and conditions.</strong>:  
I consent to the publication of this review**

Please enter your name: Annina Schmid

Job Title: A/Prof

Institution: Oxford University

Reimbursement for attending a symposium?: No

A fee for speaking?: No

A fee for organising education?: Yes

Funds for research?: Yes

Funds for a member of staff?: Yes

Fees for consulting?: No

Have you in the past five years been employed by an organisation that may in any way gain or lose financially from the publication of this paper?: No

Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper?: No

If you have any competing interests <a href="http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests" target="\_new"> (please see BMJ policy) </a>please declare them here: funds for courses on neuropathic pain. research grants from government, charities and industry.

<em>BMJ are working with <a href="https://orcid.org/" target="\_blank">ORCID</a> to recognise the importance of the reviewer community. Reviewers are now able to share their activity by connecting their review to their ORCID account to gain recognition for their contributions.

Only the Journal title will be uploaded into the reviewer's ORCID record, along with the date the record was uploaded; there is no identification of the article's title or authors. Records are uploaded once a decision (accept, reject, or revision) has been made on the article.</em>

Would you like to be accredited by <a href="https://orcid.org/" target="\_blank">ORCID</a> for this review?: Yes

**\*\*Information for submitting a revision\*\***

Deadline: Your revised manuscript should be returned within one month.

How to submit your revised article: Log into <http://mc.manuscriptcentral.com/bmj> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Once the revised manuscript is prepared, you can upload it and submit it through your Author Center. When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and Committee in the space provided. You can use this space to document any changes you make to the original manuscript and to explain your responses. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewer(s). As well as submitting your revised manuscript, we also require a copy of the manuscript with changes highlighted. Please upload this as a supplemental file with file designation 'Revised Manuscript Marked copy'. Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

When you revise and return your manuscript, please take note of all the following points about revising your article. Even if an item, such as a competing interests statement, was present and correct in the original draft of your paper, please check that it has not slipped out during revision. Please include these items in the revised manuscript to comply with BMJ style (see: <https://www.bmj.com/about-bmj/resources-authors/article-types> and <http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists>).

Items to include with your revision (see <http://www.bmj.com/about-bmj/resources-authors/article-types/research>):

1. What this paper adds/what is already known box (as described at <http://resources.bmj.com/bmj/authors/types-of-article/research>)
2. Name of the ethics committee or IRB, ID# of the approval, and a statement that participants gave informed consent before taking part. If ethics committee approval was not required, please state so clearly and explain the reasons why (see <http://resources.bmj.com/bmj/authors/editorial-policies/guidelines>.)
3. Patient confidentiality forms when appropriate (see [http://resources.bmj.com/bmj/authors/editorial-policies/copy\\_of\\_patient-confidentiality](http://resources.bmj.com/bmj/authors/editorial-policies/copy_of_patient-confidentiality)).
4. Competing interests statement (see <http://resources.bmj.com/bmj/authors/editorial-policies/competing-interests>)

5. Contributorship statement+ guarantor (see

<http://resources.bmj.com/bmj/authors/article-submission/authorship-contributorship>)

6. Transparency statement: (see

<http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/transparency-policy>)

7. Copyright statement/licence for publication (see

<http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse>)

8. Data sharing statement (see

<http://www.bmj.com/about-bmj/resources-authors/article-types/research>)

9. Funding statement and statement of the independence of researchers from funders (see

<http://resources.bmj.com/bmj/authors/article-submission/article-requirements>).

10. Patient involvement statement (see

<http://www.bmj.com/about-bmj/resources-authors/article-types/research>).

11. Please ensure the paper complies with The BMJ's style, as detailed below:

a. Title: this should include the study design eg "systematic review and meta-analysis."

b. Abstract: Please include a structured abstract with key summary statistics, as explained below (also see <http://resources.bmj.com/bmj/authors/types-of-article/research>). For every clinical trial - and for any other registered study- the last line of the abstract must list the study registration number and the name of the register.

c. Introduction: This should cover no more than three paragraphs, focusing on the research question and your reasons for asking it now.

d. Methods: For an intervention study the manuscript should include enough information about the intervention(s) and comparator(s) (even if this was usual care) for reviewers and readers to understand fully what happened in the study. To enable readers to replicate your work or implement the interventions in their own practice please also provide (uploaded as one or more supplemental files, including video and audio files where appropriate) any relevant detailed descriptions and materials. Alternatively, please provide in the manuscript urls to openly accessible websites where these materials can be found.

e. Results: Please report statistical aspects of the study in line with the Statistical Analyses and Methods in the Published Literature (SAMPL) guidelines

<http://www.equator-network.org/reporting-guidelines/sampl/>. Please include in the results section of your structured abstract (and, of course, in the article's results section) the following terms, as appropriate:

i. For a clinical trial: Absolute event rates among experimental and control groups; RRR (relative risk reduction); NNT or NNH (number needed to treat or harm) and its 95% confidence interval (or, if the trial is of a public health intervention, number helped per 1000 or 100,000.)

ii. For a cohort study: Absolute event rates over time (eg 10 years) among exposed and non-exposed groups; RRR (relative risk reduction.)

iii. For a case control study: OR (odds ratio) for strength of association between exposure and outcome.

iv. For a study of a diagnostic test: Sensitivity and specificity; PPV and NPV (positive and negative predictive values.)

v. For a systematic review and/or meta-analysis: Point estimates and confidence intervals for the main results; one or more references for the statistical package(s) used to analyse the data, eg RevMan for a systematic review. There is no need to provide a formal reference for a very widely used package that will be very familiar to general readers eg STATA, but please say in the text which version you used. For

articles that include explicit statements of the quality of evidence and strength of recommendations, we prefer reporting using the GRADE system.

Please report all outcomes that were listed in the trial registry, or explain that you will publish them elsewhere. Please clearly identify each outcome as primary, secondary, or post-hoc in the text, abstract, and any tables or figures. We expect authors to report prespecified outcomes. If outcomes in the trial registry have later been changed, please explain the reasons for the change and the dates of the change in the paper. You may report the changed outcomes, but we will expect you to also report on the originally specified outcomes unless otherwise agreed with the handling editor for your paper.

Occasionally the outcomes that are prespecified in a trial registry do not match up with those included in the trial protocol. When there are discrepancies between protocol and registry specified outcomes, we expect the paper to report and interpret the registry specified outcomes. You may also report any protocol specified outcomes, but if you do please be sure to include the date of the protocol and the point at which each outcome was added to the protocol, and explain why the registry entry differed from the protocol and why the registry was not updated to reflect any protocol changes.

f. Discussion: To minimise the risk of careful explanation giving way to polemic, please write the discussion section of your paper in a structured way. Please follow this structure: i) statement of principal findings of the study; ii) strengths and weaknesses of the study; iii) strengths and weaknesses in relation to other studies, discussing important differences in results; iv) what your study adds (whenever possible please discuss your study in the light of relevant systematic reviews and meta-analyses); v) meaning of the study, including possible explanations and implications for clinicians and policymakers and other researchers; vi) how your study could promote better decisions; vi) unanswered questions and future research

g. Footnotes and statements

Online and print publication: All original research in The BMJ is published with open access. Our open access policy is detailed here: <http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse>. The full text online version of your article, if accepted after revision, will be the indexed citable version (full details are at <http://resources.bmj.com/bmj/about-bmj/the-bmjs-publishing-model>). The print and iPad BMJ will carry an abridged version of your article. This abridged version of the article is essentially an evidence abstract called BMJ pico, which we would like you to write using the template downloadable at <http://resources.bmj.com/bmj/authors/bmj-pico>. Publication of research on bmj.com is definitive and is not simply interim "epublication ahead of print", so if you do not wish to abridge your article using BMJ pico, you will be able to opt for online only publication. Please let us know if you would prefer this option. If your article is accepted we will invite you to submit a video abstract, lasting no longer than 4 minutes, and based on the information in your paper's BMJ pico evidence abstract. The content and focus of the video must relate directly to the study that has been accepted for publication by The BMJ, and should not stray beyond the data.